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Abstract
Background: The purpose of this study was to assess the economic benefit of achieving remission among
outpatients with major depressive disorder (MDD) who are currently employed in Korea.
Methods: Cross-sectional observational study. A total of 337 outpatients with MDD with paid jobs were recruited
from 14 psychiatric clinics in Korea and were then divided into three groups as follows: new visit group (n= 128),
remitted group (n = 100) and non-remitted group (n = 109). The 17-item Hamilton Depression Rating Scale (HAM-D)
was used to decide whether a patient should be assigned to the remitted or non-remitted group. Direct medical
and non-medical costs were measured via interview with the subjects. The World Health Organization Health and
Work Performance Questionnaire (HPQ) were applied in order to measure the lost productive time (LPT) and related
productivity costs.
Results: The three groups did not show a significant difference in direct medical cost. However, the difference
between the remitted group and non-remitted group was statistically significant (25.49± 52.99 vs. 44.79± 126.55,
χ
2= 12.99, p =0.0015). The remitted group demonstrated a significant improvement in productivity (particularly
presenteeism) when compared with the new visit group (Z = −3.29, p = 0.001). Although the non-remitted group
received treatment at psychiatric clinics similar to the remitted group, it lost 33 more working hours per month,
which is compatible to $332 per month.
Conclusion: These results suggest the economic importance of achieving remission in treating depression.
Keywords: Major depressive disorder, HPQ, Lost productive time, Presenteeism, Remission
Background
The economic burden from depression can be assessed by
measuring direct costs, including medical and non-
medical expenses (i.e., transportation) and productivity
costs, particularly focusing on the wage loss at work. Prod-
uctivity costs can be higher than direct costs in mental
health problems, even though the relative composition
can be varied by the economy and health insurance cover-
age of each society [1,2]. Major Depressive Disorder
(MDD) is one of the major mental health conditions
among adults and has been shown to have a large impact
on work productivity [3,4]. The treatment of depression
has been shown to increase productivity as well as have a
favorable return-on-investment (ROI) [5-8].
When measuring productivity cost, many studies use
the concept of “lost productive time” (LPT), which con-
sists of “absenteeism” and “presenteeism.” Absenteeism
refers to the LPT caused by hours or days missed from
work (e.g., tardiness, leaving work early, sick leave) [2].
Presenteeism is defined as the estimated LPT caused by
reduced work performance while at work [9], which can
result from impaired concentration, reduced motivation,
fatigue or errors in decision-making. For depressive dis-
orders, LPT from presenteeism has been shown to ex-
ceed LPT from absenteeism, according to a recent study
performed in Korea [4].
Measuring both economic loss and work productivity
is very important for depressed patients who work for
pay, as they may be unable to maintain employment if
their productivity is severely impaired. The goal of treat-
ment for depression can vary depending on the patient’s
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formance to the maximum level might be the most crit-
ical target of receiving treatment. Improved productivity
is associated with stabilizing one’s basic condition of so-
cial life, maintaining self-esteem and even getting back
one’s purpose of living.
In this sense, it is quite obvious to say that getting better
is not enough. Many studies have consistently suggested
the importance of achieving remission, which is defined as
almost full recovery to the level of a person without de-
pression, thereby demonstrating low scores on the symp-
tom severity scale. In contrast to remission, ‘response’
means improvement of 50% or more in depressive symp-
toms on a rating scale. Depressed patients who failed to
obtain full remission portrayed a higher risk of being de-
pressed again [10] as well as continued to experience func-
tional impairment and even brain injury [11]. Zimmerman
et al. suggested three factors in patient self-assessment of
remission: the presence of features of positive mental health
(i.e., optimism, vigor, self-confidence); a return to one’sn o r -
mal self; and a return to the usual level of functioning [12].
Restoring job functioning is a key component of becoming
optimistic, self-confident and being one’so w ns e l f .
Although there are various types of antidepressants
which can be prescribed, not all patients who receive
treatment can achieve full symptom remission and regain
their original level of work performance. Furthermore, the
social stigma against depression and making visits to a
psychiatrist can hinder treatment compliance and remis-
sion achievement [13]. Thus, understanding the benefits
of gaining remission in reducing LPT would be very im-
portant for maximizing the functional outcome.
In this paper, we estimated both the direct costs and
indirect costs during the previous month. Regarding dir-
ect costs, we gathered information on outpatient medical
cost (cost of psychiatric treatment and number of out-
patient visit during the past month), transportation
expenses, and the frequency and cost of receiving sup-
plementary therapy for treating depression. Regarding
indirect costs, we selected data for patients with a paid
job and measured the loss of productivity among MDD
patients using the World Health Organization’s Health
and Work Performance Questionnaire (HPQ) [14]; we
then compared it among the three subgroups (new visit,
remitted and non-remitted group). We hypothesized
that the non-remitted group shows more severe prod-
uctivity loss than the new visit group and remitted
group; further, the severity of specific subtypes of symp-
toms can be associated with productivity loss.
Method
Subjects
The data of Korean MDD patients were derived from
the Korean Burden of Illness Study. This is a cross-
sectional, multicenter-based, naturalistic and outpatients-
based study for MDD. All patients were enrolled from 14
regional psychiatric outpatient clinics in Korea. The study
was conducted between December 2011 and September
2012. All study procedures were approved by the Institu-
tional Review Board of the Asan Medical Center and each
site. Institutional review board–approved written informed
consent was obtained from all study patients before com-
mencing the study.
The regional centers included three sites in the South dis-
tricts of Seoul: 1) Samsung Medical Center, Sungkyunkwan
University School of Medicine, 2) Asan Medical Center,
University of Ulsan College of Medicine, and 3) Seoul St.
Mary’s Hospital, Catholic University College of Medicine,
three sites in the North district of Seoul; 4) Seoul Paik
Hospital, Inje University 5) Konkuk University Medical
Center, and 6) Kyung Hee University Medical Center, two
sites in Incheon; 7) Ajou University Hospital, and 8) Gil
Medical Center, Gachon University, two sites in Daejeon;
9) Chungnam National University Hospital and 10) Eulji
University Hospital, one site in Cheonan; 11) Dankook
University Hospital, one site in Daegu; 12) Kyungpook Na-
tional University Hospital, 13) one site in Busan; Dong-a
University Medical Center, and one site in Gyeongju; 14)
Dongguk University Gyeongju Hospital.
Inclusion and exclusion criteria
The inclusion criteria were those aged between 18 to
64 years with a primary diagnosis of major depressive
disorder, single or recurrent non-psychotic, according to
the DSM-IV-TR criteria confirmed through clinical diag-
nosis by psychiatrists. The 17-item Hamilton Depression
Rating Scale (HAM-D) was applied to the patients [15].
A total 811 patients were enrolled from 14 hospitals.
Each consecutive patient was evaluated according to the
inclusion and exclusion criteria and then, allocated to
one of three groups – 1) New visit group, 2) Remitted
group (HAMD-17 <8) or 3) Non-remitted group (HAMD-
17 ≥8). Each hospital was allowed to allocate about 8
patients to each group, consecutively. Groups 2 and 3 in-
cluded patients who have received treatment for MDD for
less than 6 months in order to exclude the possibility of
bias in calculating the lost productivity cost from de-
creased social occupational function related with other
emotional problems.
The exclusion criteria were history of bipolar disorder,
schizophrenia, schizoaffective disorder, psychosis, anorexia
or bulimia nervosa, obsessive-compulsive disorder, or a
serious general medical condition.
Measure of depressive symptoms
We used the Hamilton Rating Scales for Depression
(HAM-D) to measure the severity of depressive symp-
toms at each visit [16].
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The Depression and Somatic Symptoms Scale (DSSS) was
applied in order to measure the somatic symptoms of
MDD patients [17]. It is a 22-item self-administered rating
scale, including three subscales: Depression Subscale (DS),
Pain Subscale (PS) and Somatic Subscale (SS). The DS had
12 items, including three vegetative symptoms and fatigue,
whereas the SS had 10 items, including five pain items
comprised of the 5-item PS. Each item was rated with a
score of 0–3: 0 (not at all); 1 (mild); 2 (moderate); 3 (se-
vere). The range of the sum score is thus 0–66. The scale
had good validity and reliability; higher scores demon-
strated heavier symptoms [18]. The Korean Version of
DSSS had a Cronbach's alpha of 0.90 and showed a rela-
tively high test-retest reliability (r=0.83, p <0.01) [19].
Measure of lost productive time (LPT)
We applied the Korean version of HPQ for the measure-
ment of productivity loss. The Korean version of the
HPQ was developed using conventional techniques of
translation and back-translation by bilingual psychia-
trists, maintaining equivalence with the permission of
Dr. Kessler, the original author [20].
Most of the HPQ questions ask about the status of the
most recent four-week period. In HPQ, absenteeism is
the sum of the number of absent work days multiplied
by 8 hours a day and the hours absent from partial day
absences, such as being late and leaving early from work.
Absent work days due to health problems or any other
reason are separately assessed.
Presenteeism is measured by the self-rated level of job
performance, a visual analogue scale from 0 (worst) to 10
(best), during the past 4 weeks. To ensure a precise ap-
praisal of presenteeism, the HPQ asks participants for an
estimate of colleagues’ average productivity as well as for
their own average productivity in the past year or two.
Excess lost productive time from non-remission was
calculated as the difference between the average LPT in
the remission group and the average LPT in the non-
remission group.
Calculation of indirect cost from LPT due to absenteeism
and presenteeism
The monthly cost of LPT due to absenteeism is calcu-
lated by projecting the total hours missed from work
due to health problems over the previous month multi-
plied by the standard labor hourly wage. Standard labor
hourly wage was imputed from the Survey on Labor
Conditions by Employment Type (2010) by Korea Statis-
tical Information Service, considering age, gender and
academic accomplishment level [21]. LPT due to present-
eeism is quantified as the actual work hours multiplied by
the reduced performance level (10-productivity rating)
over 10. The monthly cost of LPT due to presenteeism
was calculated as the total hours lost from reduced per-
formance for the previous month multiplied by the stand-
ard labor hourly wage.
Statistical analysis
Descriptive statistics methods (mean, median and stand-
ard deviation) were used for continuous data in MDD
patients. Frequency (N) and percentage (%) were ob-
tained for categorical data and the chi-square test was
applied in order to compare these categorical data.
ANOVA (or Kruskal-Wallis test in case of nonpara-
metric data) was performed in order to evaluate the
comparison among MDD patients groups; new visit, non-
remission and remission. Additionally, a two-sample t-test
(or Mann Whitney Wilcoxon test in the case of nonpara-
metric data) was applied in order to determine the
significance between the two groups (new visit vs. non-
remission, new visit vs. remission, non-remission vs.
remission). After determining the significance for ANOVA,
Tukey’s multiple comparison method (or Bonferroni’s
method in case of nonparametric data) was used for post-
hoc group comparisons.
All analyses were two-tailed and calculations were per-
formed using SAS® Version 9.2, SAS institute, Cary, NC,
USA.
Results
Demographics and clinical profiles
The average age of the three groups did not show a sig-
nificant difference. The remitted group also showed the
lowest HAM-D score and DSSS score among the three
groups (Table 1).
Direct cost and indirect cost for previous one month
Regarding direct costs, the non-remitted group showed
the highest direct non-medical cost compared to other
groups (χ
2=12.99, p=0.0015). When compared to the
remitted group, the non-remitted group spent more dir-
ect non-medical cost ($19.30±98.82). Direct medical
cost did not show a significant difference among the
three groups (Table 2).
Regarding the lost productivity cost, only patients who
were currently employed (128, 100 and 109 patients, re-
spectively) were included in the analysis. Actual work
hours, absent days and partial missing days due to health
problems during the past month were not statistically
significantly different among the three groups. LPT due
to absenteeism and monthly cost of absenteeism showed
a significant difference among the three groups (χ
2=6. 62 ,
p=0.0365 and χ
2=6.22, p=0.0445, respectively); however,
this significance was lost after using Bonferroni’sc o r r e c -
tion for post-hoc group comparisons (Table 3).
Regarding presenteeism, the remitted group showed
the highest self-rated job performance during the past
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2=29.80, p<0.0001), which is quite similar to
the level of rating the job performance of others (6.93±
2.11 vs. 7.28±1.69). Self-rated job performance, which
compared other people during the past month, showed a
significant difference (χ
2=26.33, p=0.0096). The remitted
group showed a significantly decreased level in LPT due
to presenteeism (69.8 hours for new visit group, 63.3 hours
in non-remitted group, and 46.2 hours in remitted group,
respectively) and the monthly cost of presenteeism
($733.4 per employee in the new visit group, $618.1 in the
non-remitted group, and $ 517.7 in the remitted group).
We also assessed the difference between the non-
remitted group and remitted group for LPT due to ab-
senteeism and presenteeism, resulting in 15.8 hours and
17.1 hours per month on average. Further, the monthly
cost of absenteeism and presenteeism, which implies the
economic benefit we can obtain from achieving remis-
sion, was calculated as $229.1 and $100.3 per month per
employee, respectively. Although the non-remitted group
received treatment at psychiatric clinics similar to the re-
mitted group, it lost 33 more working hours, which is
compatible to $332 per month.
We also assessed the correlation between LPT (absen-
teeism and presenteeism) and symptom severity mea-
sured by DSSS and HAM-D. The higher the HAM-D
score is, the higher is the LPT due to absenteeism in the
new visit group and non-remission group. The correl-
ation coefficients were statistically significant, but nu-
merically low (r=0.351, p<0.001).
Discussion
Our results indicated that employees with non-remitted
MDD cost more than those of the remitted group both
from direct costs as well as lost productivity costs. The
results are significant in two aspects. First, we confirmed
the tendency of previous studies on productivity and
psychiatric disorders, regarding ‘remission’ in depression.
The studies suggested that depression has been associated
Table 1 Demographics of subjects with new visit, remitted and non-remitted MDD
New MDD Remitted MDD Non-remitted MDD p Statistics Test
a)
(N = 128) (N = 100) (N = 109)
Sex, n(%)
Male 53(41.4) 43(43.0) 44(40.4) N.S.
Female 75(58.6) 57(57.0) 65(59.6)
Age (years) 42.22 ± 12.36 45.42 ± 11.34 45.12 ± 10.84 N.S.
Marital status, n(%)
Single 31(24.2) 20(20.0) 20(18.3) N.S.
Married 76(59.4) 64(64.0) 74(67.9)
Bereavement 5(3.9) 4(4.0) 6(5.5)
Divorced 12(9.4) 9(9.0) 8(7.3)
Separated 3(2.3) 3(3.0) 1(0.9)
Education, n(%)
Elementary school 16(12.5) 13(13.0) 10(9.2) N.S.
Middle school 19(14.8) 14(14.0) 13(11.9)
High school 37(28.9) 37(37.0) 44(40.4)
University 49(38.3) 26(26.0) 34(31.2)
Graduate school 6(4.7) 10(10.0) 8(7.3)
Onset of MDD (years) 39.67 ± 13.28 42.65 ± 11.75 42.60 ± 11.33 N.S.
Number of previous depressive episodes 0.82 ± 1.46 1.00 ± 1.24 1.37 ± 2.15 0.0461
b) F = 3.11 a = b, b = c, a < c
HAM-D scores 17.48 ± 7.17 4.39 ± 2.19 16.02 ± 5.05 <0.0001
b) F = 187.61 b < c = a
DSSS 28.09 ± 12.25 10.15 ± 9.69 27.07 ± 12.93 <0.0001
b) F = 77.38 b < c = a
DS 17.16 ± 7.04 5.96 ± 5.92 16.57 ± 7.36 <0.0001
b) F = 90.00 b < c = a
SS 10.93 ± 6.16 4.19 ± 4.32 10.48 ± 6.66 <0.0001
b) F = 43.91 b < c = a
PS 5.18 ± 3.23 2.20 ± 2.21 5.11 ± 3.62 <0.0001
b) F = 31.61 b < c = a
a)Tukey’s Post-hoc test.
b)Difference between groups (ANOVA).
Note: Denominator of percentage is the number of subjects in the column.
Categorical variables are displayed as the number of subjects (percentage of subjects).
Continuous variables are displayed as mean± sd.
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more than absenteeism [22,23]. Similarly, our results re-
vealed that all three groups of study subjects conveyed
more loss from presenteeism than those from absenteeism
while showing the least presenteeism in the remitted
group (χ
2=15 .4 9 ,p=0. 00 04 ).
Second, these data suggest that psychiatric outpatient
treatment itself cannot save substantial costs arising
from absenteeism and presenteeism without achieving
remission. We can estimate the difference in monthly cost
between the non-remission group and remission group as
$332, which amounts to 16.3% of the average employment
income of $2041 per month in Korea as of 2010.
The remitted group rated their own job performance
as 6.90 (out of a possible 10). Hence, no specific rating
score is yet defined as a normative value for the general
working population. Kessler et al. mentioned that the
majority of the workers rated their work performance as
over 7, mostly 8 to 9 [14]. Data from previous studies
showed that values for the general working population
usually fall between 7 and 8, which is a bit higher than
that of the remitted group of this study [4,20].
Given the results of this study, we can assume that the
distress among workers with MDD have measurable loss
on everyday activities. Doctors may want to relate clinical
distress and economic loss for patients with depression
and focus on how treatment can reduce the economic
loss. Such efforts could improve treatment compliance by
enhancing motivation and thus help achieve remission.
This study has some limitations. First, possible selec-
tion biases need to be considered. Due to ethical and
practical issues, we did not include a randomized control
group. Instead, we recruited patients who voluntarily vis-
ited a psychiatric clinic in order to get treatment and
were working at the moment. However, they may sys-
tematically differ from those who do not work. Even
though the three groups of subjects were not signifi-
cantly different in many demographic and work-related
variables, the average severity of depression among the
subjects of this study can be lower than the depressed
Table 2 Direct cost for previous one month
Direct cost for previous one month New MDD Remitted MDD Non-remitted MDD p Statistics Test
a)
(N = 128) (N = 100) (N = 109)
Outpatient cost
Number of visits to clinics 2.17 ± 1.39(2.00) 2.34 ± 1.51(2.00) 2.91 ± 2.27(2.00) 0.0043
b) F = 5.53 a = b < c
Cost of an outpatient treatment($) 77.30 ± 74.43(56.39) 65.94 ± 78.26(50.91) 67.07 ± 58.17(49.09) N.S.
Transportation expenses
Transportation expense for treated MDD 11.18 ± 15.17(7.27) 13.62 ± 31.47(4.18) 15.77 ± 19.09(9.09) 0.0045
c) χ
2 = 10.79 a = b < c
Time spent for transportation (hour) 1.62 ± 1.61(1.00) 1.66 ± 2.01(1.00) 1.91 ± 2.28(1.33) N.S.
Supplementary therapy
Number of subjects 9 9 12
Average monthly number of
supplementary therapy
6.11 ± 8.10(2.00) 9.33 ± 9.99(3.00) 12.25 ± 11.94(7.50) N.S.
Average cost of supplementary
therapy($)
64.95 ± 108.05(18.18) 51.31 ± 68.00(9.09) 56.35 ± 86.79(9.45) N.S.
Type of supplementary therapy, n(%)
Health supplements 3(33.3) 1(11.1) 2(16.7) N.S.
Chinese medicine, acupuncture 1(11.1) 1(11.1) 3(25.0)
Yoga, meditation, massage 4(44.4) 5(55.6) 7(58.3)
Physical therapy, exercise 1(11.1) 1(11.1) 0(0.0)
Etc. 0(0.0) 1(11.1) 0(0.0)
Direct medical cost
d) 90.59 ± 84.77(59.09) 76.36 ± 81.47(54.55) 90.36 ± 85.45(61.99) N.S.
Direct non-medical cost
e) 21.10 ± 55.11(9.09) 25.49 ± 52.99(5.64) 44.79 ± 126.55(14.55) 0.0015
c) χ
2 = 12.99 a=b<c
a)Tukey’s Post-hoc test.
b)Difference between groups (ANOVA).
c)Difference between groups (Kruskal-Wallis test).
d)Direct cost = number of outpatient treatment × cost of an outpatient treatment.
e)Direct non-medical cost = transportation expense for treated MDD × number of outpatient treatment during the past month + average cost of supplementary
therapy × average monthly number of supplementary therapy.
Note: Denominator of percentage is the number of subjects in the column.
Categorical variables are displayed as the number of subjects (percentage of subjects).
Continuous variables are displayed as mean± standard deviation (median).
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the new visit group and non-remitted group rated their
own job performance as 5.4 ±2.37 and 5.5 ±2.49, re-
spectively, which are approximately 20% higher than the
results from workers with MDD in a previous study [4].
It is also possible that some patients could not maintain
their jobs due to MDD, and thus were excluded from this
study even if they can be included in the labor force.
Therefore, the lost productivity cost from LPT in this study
could be underestimated than that in the previous study.
Table 3 Lost productivity for previous one month
Lost productive time for previous
one month
New MDD Remitted MDD Non-remitted MDD p Statistics Test
a)
(N = 128) (N = 100) (N = 109)
Actual work (days) 24.20 ± 4.73(25) 23.95 ± 5.41(25) 24.12 ± 5.97(25) N.S.
Absent days due to health problems 3.42 ± 6.74(0) 2.83 ± 7.19(0) 4.90 ± 8.69(0) N.S.
Partial missing days due to health problems 2.16 ± 4.32(0) 1.69 ± 4.59(0) 2.61 ± 5.70(0) N.S.
Other person rating job performance 6.73 ± 2.16(7) 7.28 ± 1.69(7) 6.49 ± 2.33(7) N.S.
Self-rated job performance 5.38 ± 2.37(5) 6.93 ± 2.11(7) 5.47 ± 2.49(5) <0.0001
b) χ
2 = 29.80
Self-rated job performance compared
other person, n (%)
Extremely better 7(5.5) 11(11.0) 8(7.3) 0.0096
c) χ
2 = 26.33
Quite better 15(11.7) 15(15.0) 10(9.2)
Slightly better 10(7.8) 13(13.0) 4(3.7)
Neither 30(23.4) 30(30.0) 25(22.9)
Slightly worse 23(18.0) 14(14.0) 23(21.1)
Quite worse 25(19.5) 10(10.0) 13(11.9)
Extremely worse 18(14.1) 7(7.0) 26(23.9)
LPT due to Absenteeism
e) (hour) 29.59 ± 51.29(2) 23.15 ± 53.14(0) 38.93 ± 65.69(0) 0.0365
b) χ
2 = 6.62 a=b=c
LPT due to Presenteeism
f) (hour) 69.76 ± 45.71(66) 46.19 ± 31.44(45) 63.27 ± 47.27(64) 0.0004
b) χ
2 = 15.49 a=c ,a>b ,
c>b
Monthly Cost of Absenteeism
g) ($) 262.29 ± 438.70(0) 220.25 ± 470.86(0) 449.34 ± 876.63(0) 0.0445
b) χ
2 = 6.22 a = b = c
Monthly Cost of Presenteeism
h) ($) 733.43 ± 630.39
(559)
517.74 ± 483.64
(401)
618.09 ± 563.58
(528)
0.0196
b) χ
2 = 7.86 c = b < a
Difference between New and Remitted
MDD for LPT due to Absenteeism (hour)
- 6.44 ± 52.10 - 0.0244
d) Z=−2.25 -
Difference between New and Remitted
MDD for LPT due to Presenteeism (hour)
- 23.57 ± 40.13 - <0.0001
d) Z=−4.00 -
Difference between Non-remitted and Remitted
MDD for LPT due to Absenteeism (hour)
- - 15.77 ± 60.02 0.0205
d) Z=−2.32 -
Difference between Non-remitted and Remitted
MDD for LPT due to Presenteeism (hour)
- - 17.08 ± 40.48 0.0140
d) Z=−2.46 -
Difference of non-remitted MDD from remitted
MDD for Monthly Cost of Absenteeism ($)
- - 229.11 ± 712.10 0.0205
d) Z=−2.32 -
Difference of non-remitted MDD from remitted
MDD for Monthly Cost of Presenteeism ($)
- - 100.35 ± 526.92 0.2347
d) Z=−1.19 -
Total cost ($) 1105.55 ± 678.80
(990)
846.47 ± 698.00
(629)
1202.36 ± 885.49
(951)
0.0005
b) χ
2 = 15.26 a=c ,a>b ,
c>b
a)Mann Whitney Wilcoxon test for multiple comparison (Bonferroni's correction method).
b)Difference between groups (Kruskal-Wallis test).
c)Difference between groups (Chi-square test).
d)Difference between groups (Mann Whitney Wilcoxon test).
e)LPT due to Absenteeism = Absent days due to health problems× 8(hours) + Partial missing days due to health problems× 4(hours).
f)LPT due to Presenteeism=[{Actual work (days)×8(hours)-Absent days due to health problems×8(hours)-Partial missing days due to health problems×4(hours)}×
{(10-Self-rated job performance)/10}].
g)Monthly cost of Absenteeism = LPT of Absenteeism × hourly wage.
h)Monthly cost of Presenteeism = LPT of Presenteeism × hourly wage.
Note: Denominator of percentage is the number of subjects in the column.
Categorical variables are displayed as the number of subjects (percentage of subjects).
Continuous variables are displayed as mean± standard deviation (median).
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to the time of the assessments. In these cases, the subject
may report more severe work productivity loss over the
course of the past 4 weeks in spite of reporting few de-
pressive symptoms at the time of measurement.
Last but not the least, we must be careful not to make
any crude inference regarding the causality in the cross-
sectional study of this type.
Conclusions
As discussed, residual symptoms and non-remission are
known to be associated with impairment in social func-
tioning, low quality of life and extensive health care
utilization. Obtaining full remission of depressive symp-
toms is of crucial importance not only for reducing clinical
distress, but also for reducing the socio-economic burden.
Abbreviations
MDD: Major Depressive Disorder; HAM-D: The 17-item Hamilton Depression
Rating Scale; HPQ: The World Health Organization Health and Work Performance
Questionnaire; LPT: The lost productive time; DSM-IV-TR: Diagnostic and
Statistical Manual of Mental Disorders-IV-Text Revision; DSSS: The Depression
and Somatic Symptoms Scale; DS: Depression Subscale; PS: Pain Subscale;
SS: Somatic Subscale.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
J-M W and JPH designed the study, performed the analysis, and wrote the
manuscript. J-M W, HJJ, K-HL, CUL, JSN, CHL collected the data. HJK and HJJ
participated in the analysis and interpretation of data. All authors read and
approved the final manuscript.
Acknowledgement
This study was supported by Pfizer Pharmaceuticals Korea Ltd. by the Basic
Science Research Program through the National Research Foundation of
Korea (NRF) of the Ministry of Education, Science and Technology
(No. 2011–0013064).
Author details
1Department of Psychiatry, Seoul Paik Hospital, Inje University School of
Medicine, Seoul, Korea.
2Stress Research Institute, Inje University, Seoul, Korea.
3Department of Psychiatry, Depression Center, Samsung Medical Center,
Sungkyunkwan University School of Medicine, Seoul, Korea.
4Depression
Clinical and Research Program, Massachusetts General Hospital, Harvard
Medical School, Boston, USA.
5OR/EBM Team, Market Access Division, Pfizer
Pharmaceuticals Korea Limited, Seoul, Korea.
6Department of Psychiatry,
Dongguk University College of Medicine, Gyeongju, Korea.
7Department of
Psychiatry, College of Medicine, The Catholic University of Korea, Seoul,
Korea.
8Department of Psychiatry, Ajou University School of Medicine,
Suwon, Korea.
9Department of Psychiatry, Eulji University School of Medicine,
Daejeon, Korea.
10Department of Psychiatry, Asan Medical Center, University
of Ulsan College of Medicine, Seoul, South Korea.
Received: 13 May 2014 Accepted: 16 October 2014
Published: 15 November 2014
References
1. Collins JJ, Baase CM, Sharda CE, Ozminkowski RJ, Nicholson S, Billotti GM,
Turpin RS, Olson M, Berger ML: The assessment of chronic health
conditions on work performance, absence, and total economic impact
for employers. J Occup Environ Med 2005, 47:547–557.
2. Stewart WF, Ricci JA, Chee E, Morganstein D, Lipton R: Lost productive
time and cost due to common pain conditions in the US workforce.
JAMA 2003, 290:2443–2454.
3. Druss BG, Rosenheck RA, Sledge WH: Health and disability costs of
depressive illness in a major U.S. corporation. Am J Psychiatry 2000,
157:1274–1278.
4. Woo JM, Kim W, Hwang TY, Frick KD, Choi BH, Seo YJ, Kang EH, Kim SJ,
Ham BJ, Lee JS, Park YL: Impact of depression on work productivity and
its improvement after outpatient treatment with antidepressants. Value
Health 2011, 14:475–482.
5. Berndt ER, Finkelstein SN, Greenberg PE, Howland RH, Keith A, Rush AJ,
Russell J, Keller MB: Workplace performance effects from chronic
depression and its treatment. J Health Econ 1998, 17:511–535.
6. Rost K, Smith JL, Dickinson M: The effect of improving primary care
depression management on employee absenteeism and productivity A
randomized trial. Med Care 2004, 42:1202–1210.
7. Simon GE, Barber C, Birnbaum HG, Frank RG, Greenberg PE, Rose RM, Wang
PS, Kessler RC: Depression and work productivity: the comparative costs
of treatment versus nontreatment. J Occup Environ Med 2001, 43:2–9.
8. Wang PS, Patrick A, Avorn J, Azocar F, Ludman E, McCulloch J, Simon G,
Kessler R: The costs and benefits of enhanced depression care to
employers. Arch Gen Psychiatry 2006, 63:1345–1353.
9. Brouwer WB, Koopmanschap MA, Rutten FF: Productivity losses without
absence: measurement validation and empirical evidence. Health Policy
1999, 48:13–27.
10. Judd LL, Akiskal HS, Maser JD, Zeller PJ, Endicott J, Coryell W, Paulus MP,
Kunovac JL, Leon AC, Mueller TI, Rice JA, Keller MB: Major depressive
disorder: A prospective study of residual subthreshold depressive
symptoms as predictor of rapid relapse. J Affect Disord 1998, 50:97–108.
11. Frodl TS, Koutsouleris N, Bottlender R, Born C, Jaeger M, Scupin I, Reiser M,
Moeller HJ, Meisenzahl EM: Depression-related variation in brain
morphology over 3 years: Effects of stress? Arch Gen Psychiatry 2008,
65:1156–1165.
12. Zimmerman M, McGlinchey JB, Posternak MA, Friedman M, Attiullah N,
Boerescu D: How should remission from depression be defined? The
depressed patient's perspective. Am J Psychiatry 2006, 163:148–150.
1 3 . W a n gP S ,B e r g l u n dP ,O l f s o nM ,P i n c u sH A ,W e l l sK B ,K e s s l e rR C :Failure and
delay in initial treatment contact after first onset of mental disorders in the
National Comorbidity Survey Replication. Arch Gen Psychiatry 2005, 62:603–613.
14. Kessler RC, Barber C, Beck A, Berglund P, Cleary PD, McKenas D, Pronk N,
Simon G, Stang P, Ustun TB, Wang P: The World Health Organization
Health and Work Performance Questionnaire (HPQ). J Occup Environ Med
2003, 45:156–174.
15. Hamilton M: Development of a rating scale for primary depressive illness.
Br J Soc Clin Psychol 1967, 6:278–296.
16. Clark D, Salkovskis P, Hackmann A, Middleton H, Anastasiades P, Gelder M: A
comparison of cognitive therapy, applied relaxation and imipramine in
the treatment of panic disorder. Br J Psychiatry 1994, 164:759.
17. Wei HT, Chen MH, Huang PC, Bai YM: The association between online
gaming, social phobia, and depression: an internet survey. BMC Psychiatry
2012, 12:92.
18. Hung CI, Wang SJ, Liu CY: Validation of the Depression and Somatic
Symptoms Scale by comparison with the Short Form 36 scale among
psychiatric outpatients with major depressive disorder. Depress Anxiety
2009, 26:583–591.
19. Kim KW, Hong JP, Park SJ, Choi JH, Choi HR: Reliability and Validity of
Korean Version of Depression and Somatic Symptom Scale(DSSS). Anxiety
Mood 2011, 7:9–15.
20. Park YL, Kim W, Chae JH, Oh KS, Frick KD, Woo JM: Impairment of work
productivity in panic disorder patients. J Affect Disord 2014, 157:60–65.
21. Survey on Labor Conditions by Employment Type. [http://kosis.kr/popup/
abroadPopup.jsp?method=detail&sid=2001016]
22. Sanderson K, Andrews G: Common mental disorders in the workforce:
recent findings from descriptive and social epidemiology. Can J
Psychiatry 2006, 51:63–75.
23. Goetzel RZ, Long SR, Ozminkowski RJ, Hawkins K, Wang S, Lynch W: Health,
absence, disability, and presenteeism cost estimates of certain physical
and mental health conditions affecting U.S. employers. J Occup Environ
Med 2004, 46(4):398–412.
doi:10.1186/1752-4458-8-42
Cite this article as: Woo et al.: Excess cost of non-remission among out-
patients with major depressive disorder. International Journal of Mental
Health Systems 2014 8:42.
Woo et al. International Journal of Mental Health Systems 2014, 8:42 Page 7 of 7
http://www.ijmhs.com/content/8/1/42